PIPELINE

WAY FORWARD

Targeting Neurodegenerative and Rare Diseases

EXTENSIVE THERAPEUTIC POTENTIAL

Miramoon Pharma’s compounds stabilize the binding of a specific isomerase protein with intracellular calcium channels and normalize cytosolic calcium levels in cells suffering from oxidative stress.

They have an enormous therapeutic potential in pathologies that present a primary or secondary dysfunction in underlying calcium mechanisms, which is present in several dystrophinopathies and neurodegenerative diseases.



    For detailed information about the progress of the company or investing options, leave us a message and we will organize a video meeting with our team.

    This website uses cookies to remember users and understand ways to enhance their experience.    More info
    Privacidad